Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
99 hedge funds and large institutions have $205M invested in Accelerate Diagnostics in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 36 increasing their positions, 36 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 36
3% less capital invested
Capital invested by funds: $211M → $205M (-$6.05M)
14% less funds holding
Funds holding: 115 → 99 (-16)
50% less call options, than puts
Call options by funds: $1.1M | Put options by funds: $2.22M
76% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$5.98M |
| 2 |
Rafferty Asset Management
New York
|
+$2.86M |
| 3 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
+$852K |
| 4 |
BlackRock
New York
|
+$672K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$622K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.9M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$9.87M |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$3.98M |
| 4 |
Two Sigma Investments
New York
|
-$1.64M |
| 5 |
OCMI
Oaktop Capital Management II
Chatham,
New Jersey
|
-$1.18M |
AXDX Hedge Fund Activity: Q1 2021 in Review
99 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q1 2021, worth a combined $205M — down 2.9% from $211M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of AXDX and 4 opened new positions — a net loss of 13 holders — while 36 trimmed existing stakes and 36 added.
The largest buyer was William Blair & Company, adding an estimated $5.98M. The largest seller was Fidelity Investments, exiting entirely with an estimated $10.9M sold.
- 99 institutional investors held Accelerate Diagnostics (AXDX) as of Q1 2021, down from 115 in Q4 2020.
- Funds reported $205M of Accelerate Diagnostics stock for Q1 2021, down 2.9% quarter-over-quarter.
- 4 funds opened new Accelerate Diagnostics positions in Q1 2021 and 17 closed out, a net change of -13 holders.
- The largest Accelerate Diagnostics buyer in Q1 2021 was William Blair & Company, an estimated $5.98M added.
- The largest Accelerate Diagnostics seller in Q1 2021 was Fidelity Investments, an estimated $10.9M sold.
Based on aggregated 13F filings for Q1 2021.